Eli Lilly and Purdue University Launch Five-Year Collaboration

Eli Lilly and Company and Purdue University have formed a strategic collaboration to conduct life science research. The five-year agreement, where Lilly will provide up to $52 million, marks Purdue's largest strategic collaboration with a single company.

The initial research focus areas include:

• Developing improved delivery of injectable medicines with the goals of reducing pain, decreasing the number of injections, and enabling better patient compliance and overall health.

• Developing predictive models for clinical success that reduce risks associated with investing in drug development and more effectively predict the outcome of new therapies in humans.

In the future, the partners say, collaboration may extend to other areas to best utilize the range of expertise at the two institutions. Purdue researchers from the natural and physical sciences, engineering and veterinary medicine will collaborate with Lilly researchers.

"The biomedical revolution is upon us, but harnessing its full potential will require strong collaboration between academic research centers and industry partners," said David Ricks, Lilly's chairman, president and chief executive officer. "We look forward to expanding our relationship with Purdue as we work together to discover breakthrough solutions for patients."

Source: PRNewswire